Synergistic actions between angiotensin-converting enzyme inhibitors and statins in atherosclerosis
Hypertension and hypercholesterolemia are independent risk factors for atherosclerotic cardiovascular disease (ASCVD) by acting directly on the endothelium and activating the renin-angiotensin aldosterone system (RAAS) and mevalonate pathways. This review examines how the severity and duration of th...
Gespeichert in:
| Veröffentlicht in: | Nutrition, metabolism, and cardiovascular diseases metabolism, and cardiovascular diseases, 2022-04, Vol.32 (4), p.815-826 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 826 |
|---|---|
| container_issue | 4 |
| container_start_page | 815 |
| container_title | Nutrition, metabolism, and cardiovascular diseases |
| container_volume | 32 |
| creator | Borghi, Claudio Levy, Bernard I. |
| description | Hypertension and hypercholesterolemia are independent risk factors for atherosclerotic cardiovascular disease (ASCVD) by acting directly on the endothelium and activating the renin-angiotensin aldosterone system (RAAS) and mevalonate pathways. This review examines how the severity and duration of these risk factors may influence the cardiovascular risk through a reciprocal interplay leading to oxidative stress and pro-inflammatory response.
The review highlights the clinical evidence supporting the benefits of statins and angiotensin-converting enzyme (ACE) inhibitors for hypertension, lipid disorders and ASCVD management, both individually and combined, at all stages of the cardiovascular continuum.
Drug strategies incorporating an ACE-inhibitor and a statin, and in particular perindopril and atorvastatin, have consistently demonstrated reductions in the rate of ASCVD events in patients with hypertension and lipid disorders, cementing their position as first-line therapies for the management of atherosclerosis complications. |
| doi_str_mv | 10.1016/j.numecd.2021.11.015 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2623325652</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0939475321005561</els_id><sourcerecordid>2623325652</sourcerecordid><originalsourceid>FETCH-LOGICAL-c408t-b4f1bc26ac2e7128ddbeceb91baf2cd43102c0331d7172e008aa494aa5bd51f23</originalsourceid><addsrcrecordid>eNp9kMFu2zAMQIWhQ5t2_YNh8LEXe6RkxfGlQFF0W4ECO2w7CxJFpwpiuZOUDtnXz0HaHnehAPJRJJ8QHxEaBFx-3jRxNzL5RoLEBrEB1O_EAnUPtepkfyIW0Ku-bjutzsR5zhsA1YFqT8WZ0rCSoPVC0I995LQOuQSqLJUwxVw5Ln-YY2XjOkyFYw6xpik-cyohriuOf_cjVyE-BhfKlPIM-ioXO1fznK5seeQ0ZdoeYsgfxPvBbjNfvrwX4teXu5-33-qH71_vb28eamphVWrXDuhILi1J7lCuvHdM7Hp0dpDkW4UgCZRC32EnGWBlbdu31mrnNQ5SXYir479Pafq941zMGDLxdmsjT7ts5FIqJfVSH9D2iNK8YU48mKcURpv2BsEc9JqNOeo1B70G0cx657ZPLxN2bmT_1vTqcwaujwDPdz4HTiZT4EjsQ2Iqxk_h_xP-AWEXkLo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2623325652</pqid></control><display><type>article</type><title>Synergistic actions between angiotensin-converting enzyme inhibitors and statins in atherosclerosis</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Borghi, Claudio ; Levy, Bernard I.</creator><creatorcontrib>Borghi, Claudio ; Levy, Bernard I.</creatorcontrib><description>Hypertension and hypercholesterolemia are independent risk factors for atherosclerotic cardiovascular disease (ASCVD) by acting directly on the endothelium and activating the renin-angiotensin aldosterone system (RAAS) and mevalonate pathways. This review examines how the severity and duration of these risk factors may influence the cardiovascular risk through a reciprocal interplay leading to oxidative stress and pro-inflammatory response.
The review highlights the clinical evidence supporting the benefits of statins and angiotensin-converting enzyme (ACE) inhibitors for hypertension, lipid disorders and ASCVD management, both individually and combined, at all stages of the cardiovascular continuum.
Drug strategies incorporating an ACE-inhibitor and a statin, and in particular perindopril and atorvastatin, have consistently demonstrated reductions in the rate of ASCVD events in patients with hypertension and lipid disorders, cementing their position as first-line therapies for the management of atherosclerosis complications.</description><identifier>ISSN: 0939-4753</identifier><identifier>EISSN: 1590-3729</identifier><identifier>DOI: 10.1016/j.numecd.2021.11.015</identifier><identifier>PMID: 35082055</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Angiotensin-Converting Enzyme Inhibitors - adverse effects ; Angiotensins - pharmacology ; Angiotensins - therapeutic use ; Atherosclerosis - drug therapy ; Atherosclerosis - prevention & control ; Atorvastatin - adverse effects ; Cardiovascular Diseases - drug therapy ; Clinical trials ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects ; Hyperlipidemia ; Hypertension ; Pharmacology ; Renin-Angiotensin System</subject><ispartof>Nutrition, metabolism, and cardiovascular diseases, 2022-04, Vol.32 (4), p.815-826</ispartof><rights>2022 The Authors</rights><rights>Copyright © 2022 The Authors. Published by Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c408t-b4f1bc26ac2e7128ddbeceb91baf2cd43102c0331d7172e008aa494aa5bd51f23</citedby><cites>FETCH-LOGICAL-c408t-b4f1bc26ac2e7128ddbeceb91baf2cd43102c0331d7172e008aa494aa5bd51f23</cites><orcidid>0000-0001-8039-8781</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.numecd.2021.11.015$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35082055$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Borghi, Claudio</creatorcontrib><creatorcontrib>Levy, Bernard I.</creatorcontrib><title>Synergistic actions between angiotensin-converting enzyme inhibitors and statins in atherosclerosis</title><title>Nutrition, metabolism, and cardiovascular diseases</title><addtitle>Nutr Metab Cardiovasc Dis</addtitle><description>Hypertension and hypercholesterolemia are independent risk factors for atherosclerotic cardiovascular disease (ASCVD) by acting directly on the endothelium and activating the renin-angiotensin aldosterone system (RAAS) and mevalonate pathways. This review examines how the severity and duration of these risk factors may influence the cardiovascular risk through a reciprocal interplay leading to oxidative stress and pro-inflammatory response.
The review highlights the clinical evidence supporting the benefits of statins and angiotensin-converting enzyme (ACE) inhibitors for hypertension, lipid disorders and ASCVD management, both individually and combined, at all stages of the cardiovascular continuum.
Drug strategies incorporating an ACE-inhibitor and a statin, and in particular perindopril and atorvastatin, have consistently demonstrated reductions in the rate of ASCVD events in patients with hypertension and lipid disorders, cementing their position as first-line therapies for the management of atherosclerosis complications.</description><subject>Angiotensin-Converting Enzyme Inhibitors - adverse effects</subject><subject>Angiotensins - pharmacology</subject><subject>Angiotensins - therapeutic use</subject><subject>Atherosclerosis - drug therapy</subject><subject>Atherosclerosis - prevention & control</subject><subject>Atorvastatin - adverse effects</subject><subject>Cardiovascular Diseases - drug therapy</subject><subject>Clinical trials</subject><subject>Humans</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects</subject><subject>Hyperlipidemia</subject><subject>Hypertension</subject><subject>Pharmacology</subject><subject>Renin-Angiotensin System</subject><issn>0939-4753</issn><issn>1590-3729</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kMFu2zAMQIWhQ5t2_YNh8LEXe6RkxfGlQFF0W4ECO2w7CxJFpwpiuZOUDtnXz0HaHnehAPJRJJ8QHxEaBFx-3jRxNzL5RoLEBrEB1O_EAnUPtepkfyIW0Ku-bjutzsR5zhsA1YFqT8WZ0rCSoPVC0I995LQOuQSqLJUwxVw5Ln-YY2XjOkyFYw6xpik-cyohriuOf_cjVyE-BhfKlPIM-ioXO1fznK5seeQ0ZdoeYsgfxPvBbjNfvrwX4teXu5-33-qH71_vb28eamphVWrXDuhILi1J7lCuvHdM7Hp0dpDkW4UgCZRC32EnGWBlbdu31mrnNQ5SXYir479Pafq941zMGDLxdmsjT7ts5FIqJfVSH9D2iNK8YU48mKcURpv2BsEc9JqNOeo1B70G0cx657ZPLxN2bmT_1vTqcwaujwDPdz4HTiZT4EjsQ2Iqxk_h_xP-AWEXkLo</recordid><startdate>202204</startdate><enddate>202204</enddate><creator>Borghi, Claudio</creator><creator>Levy, Bernard I.</creator><general>Elsevier B.V</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-8039-8781</orcidid></search><sort><creationdate>202204</creationdate><title>Synergistic actions between angiotensin-converting enzyme inhibitors and statins in atherosclerosis</title><author>Borghi, Claudio ; Levy, Bernard I.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c408t-b4f1bc26ac2e7128ddbeceb91baf2cd43102c0331d7172e008aa494aa5bd51f23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Angiotensin-Converting Enzyme Inhibitors - adverse effects</topic><topic>Angiotensins - pharmacology</topic><topic>Angiotensins - therapeutic use</topic><topic>Atherosclerosis - drug therapy</topic><topic>Atherosclerosis - prevention & control</topic><topic>Atorvastatin - adverse effects</topic><topic>Cardiovascular Diseases - drug therapy</topic><topic>Clinical trials</topic><topic>Humans</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects</topic><topic>Hyperlipidemia</topic><topic>Hypertension</topic><topic>Pharmacology</topic><topic>Renin-Angiotensin System</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Borghi, Claudio</creatorcontrib><creatorcontrib>Levy, Bernard I.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Nutrition, metabolism, and cardiovascular diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Borghi, Claudio</au><au>Levy, Bernard I.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Synergistic actions between angiotensin-converting enzyme inhibitors and statins in atherosclerosis</atitle><jtitle>Nutrition, metabolism, and cardiovascular diseases</jtitle><addtitle>Nutr Metab Cardiovasc Dis</addtitle><date>2022-04</date><risdate>2022</risdate><volume>32</volume><issue>4</issue><spage>815</spage><epage>826</epage><pages>815-826</pages><issn>0939-4753</issn><eissn>1590-3729</eissn><abstract>Hypertension and hypercholesterolemia are independent risk factors for atherosclerotic cardiovascular disease (ASCVD) by acting directly on the endothelium and activating the renin-angiotensin aldosterone system (RAAS) and mevalonate pathways. This review examines how the severity and duration of these risk factors may influence the cardiovascular risk through a reciprocal interplay leading to oxidative stress and pro-inflammatory response.
The review highlights the clinical evidence supporting the benefits of statins and angiotensin-converting enzyme (ACE) inhibitors for hypertension, lipid disorders and ASCVD management, both individually and combined, at all stages of the cardiovascular continuum.
Drug strategies incorporating an ACE-inhibitor and a statin, and in particular perindopril and atorvastatin, have consistently demonstrated reductions in the rate of ASCVD events in patients with hypertension and lipid disorders, cementing their position as first-line therapies for the management of atherosclerosis complications.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>35082055</pmid><doi>10.1016/j.numecd.2021.11.015</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0001-8039-8781</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0939-4753 |
| ispartof | Nutrition, metabolism, and cardiovascular diseases, 2022-04, Vol.32 (4), p.815-826 |
| issn | 0939-4753 1590-3729 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2623325652 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Angiotensin-Converting Enzyme Inhibitors - adverse effects Angiotensins - pharmacology Angiotensins - therapeutic use Atherosclerosis - drug therapy Atherosclerosis - prevention & control Atorvastatin - adverse effects Cardiovascular Diseases - drug therapy Clinical trials Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects Hyperlipidemia Hypertension Pharmacology Renin-Angiotensin System |
| title | Synergistic actions between angiotensin-converting enzyme inhibitors and statins in atherosclerosis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T12%3A45%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Synergistic%20actions%20between%20angiotensin-converting%20enzyme%20inhibitors%20and%20statins%20in%20atherosclerosis&rft.jtitle=Nutrition,%20metabolism,%20and%20cardiovascular%20diseases&rft.au=Borghi,%20Claudio&rft.date=2022-04&rft.volume=32&rft.issue=4&rft.spage=815&rft.epage=826&rft.pages=815-826&rft.issn=0939-4753&rft.eissn=1590-3729&rft_id=info:doi/10.1016/j.numecd.2021.11.015&rft_dat=%3Cproquest_cross%3E2623325652%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2623325652&rft_id=info:pmid/35082055&rft_els_id=S0939475321005561&rfr_iscdi=true |